Generally studies have found lowering of HbA1c values to be positive, however, some question marks have arisen about whether certain therapies may carry more danger.
The ACCORD study, discussed in further detail below, is an example of a study in which death rates were noticeably higher in the intensive therapy group.
No explicit reason was given for why and, within the medical profession, this has lead practitioners and consultants to question whether HbA1c targets under 7% should be achieved.
However, a number of commentators have since questioned the involvement of the now banned drug Avandia in the study and contest that a lower HbA1c, in itself, should not be isolated as the reason for the higher death rate.